Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs (Q28378007)

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

New horizons in the treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

DNA microarrays in drug discovery and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Microarrays: biotechnology's discovery platform for functional genomics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Genome analysis with gene expression microarrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Drug target validation and identification of secondary drug target effects using DNA microarrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

'Proteomic contigs' of Mycobacterium tuberculosis and Mycobacterium bovis (BCG) using novel immobilised pH gradients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Pharmacogenomics - it's not just pharmacogenetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

The new partnership of genomics and chemistry for accelerated drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

A scoring scheme for discriminating between drugs and nondrugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Effect of Lipophilicity at N-1 on Activity of Fluoroquinolones against Mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

FDA approves tuberculosis drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Effects of Ethionamide and Isoxyl on Mycolic Acid Synthesis in Mycobacterium tuberculosis bcg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Mycolic acid synthesis: a target for ethionamide in mycobacteria?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Distribution, induction and purification of a monooxygenase catalyzing sulphoxidation of drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Antituberculosis activity of substituted thioureas. IV. Studies with 4-butoxy-4'-dimethylaminothiocarbanilide (Su 1906)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Resistance to the nitroheterocyclic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Reductive activation of nitroheterocyclic compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Rifamycin resistance in mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

inferred from DOI database lookup

7 January 2021

based on heuristic

katG mutations in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from Finnish patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900253-1